Author

Sonya Snedecor

VEDOLIZUMAB IV VERSUS ADALIMUMAB TO TREAT MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: COST-EFFECTIVENESS FROM A US PRIVATE PAYER PERSPECTIVE
VEDOLIZUMAB IV VERSUS ADALIMUMAB TO TREAT MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: COST-EFFECTIVENESS FROM A US PRIVATE PAYER PERSPECTIVE

Sonya Snedecor  et al.

Item 1 - 1 / 1
1